DNMT1 and acute myeloid leukemia: Currently, two DNMT inhibitors (DNMTi), the nucleoside analogues, 5-azacitydine (azacitidine) and 5-aza-2′-deoxycytidine (decitabine), have been approved by Food and Drug Administration (FDA) and the European Medicines Agency (EMA) against myelodysplastic syndromes (MDS), AML, and chronic myelomonocytic leukemia (CMML).